- Celgene (NASDAQ:CELG) eases 3% after hours on robust volume in response to its announcement that it will not seek a new indication for Revlimid (lenalidomide) as maintenance therapy in patients with diffuse large B-cell lymphoma (DLBCL) who responded to first-line rituximab (Roche's Rituxan) plus R-CHOP chemo.
- The company's decision was based on the results from a randomized Phase 3 study, REMARC, that showed a statistically valid improvement in progression-free survival in the treatment group versus placebo, but no difference in overall survival.
- Revlimid is currently approved for multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma.